Lack of nephrotoxic effects of the new quinolone antibacterial agent levofloxacin in rabbits.
The nephrotoxicity of (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1- piperazinyl)-7-oxo-7H-pyrido [1,2,3-de][1,4]benzoxazine-6-carboxylic acid hemihydrate (levofloxacin, DR-3355, CAS 100986-85-4), a new quinolone antibacterial agent, was evaluated in male New Zealand White (NZW) rabbits after oral administration of 30 or 120 mg/kg for 10 days. Although reduced body weight gain was observed in the 120 mg/kg, DR-3355 induced no change in function and morphology of the kidneys at both doses.